Verition Fund Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Verition Fund Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-75,000	Closed	-$3.93M	–	3093
2021 Q4	$3.93M	Hold	75,000	–	–	0.03%	477
2021 Q3	$2.8M	Buy	+75,000	New	+$2.61M	0.02%	462
2020 Q1	–	Sell	-51,300	Closed	-$1.76M	–	1121
2019 Q4	$1.76M	Buy	+51,300	New	+$616K	0.03%	289
2019 Q3	–	Sell	-35,000	Closed	-$454K	–	1384
2019 Q2	$454K	Buy	+35,000	New	+$449K	0.01%	702

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Verition Fund Management's ITCI Position: Q2 2025 in Review

Verition Fund Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 301,923 shares — an estimated $39.8M sold.

Verition Fund Management first reported a position in ITCI in Q3 2019 and held it in 17 quarters. The position peaked at $39.8M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Verition Fund Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Verition Fund Management sold 301,923 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $39.8M.
Verition Fund Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2019 and held it in 17 quarters.
Verition Fund Management's Intra-Cellular Therapies Inc. position peaked at $39.8M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.